Molnupiravir was developed in response to an urgent unmet need for an orally administered antiviral drug to prevent disease progression in patients with COVID-19. Dr Nagalingeswaran Kumarasamy (Voluntary Health Services Hospital, Chennai, Southern India) discusses the phase III study assessing the efficacy and safety of molnupiravir in Indian patients with mild SARS-CoV2 infection.
The abstract entitled: ‘Phase III Trial of Molnupiravir in Adults with Mild Sars-Cov-2 Infection in India’ (Abstract #101) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
Questions:
- Could you give us a brief overview of the Phase III Molnupiravir clinical trial in India, and the key study findings? (0:34)
- What questions remain unanswered and what will be the next steps for Molnupiravir as a treatment for COVID-19? (6:14)
Disclosures: Nagalingeswaran Kumarasamy has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022
